Lv11
80 积分 2024-03-06 加入
Treatment of Relapsed and Refractory Follicular Lymphoma: Which Treatment for Which Patient for Which Line of Therapy?
3小时前
求助中
Non-V600E BRAF mutations and treatment for hairy cell leukemia
4个月前
已关闭
Do we need another TKI for chronic myeloid leukaemia?
4个月前
已完结
Features of Toxoplasma gondii reactivation after allogeneic hematopoietic stem-cell transplantation in a high seroprevalence setting
5个月前
已完结
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML
6个月前
已关闭
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML
6个月前
已关闭
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML
6个月前
已关闭
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
7个月前
已关闭
FDA-approved therapies for chronic GVHD
7个月前
已关闭
皖公网安备34019202002308
